Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET

Company Participants

Michael Parks - VP, IR

Lishan Aklog - Chairman, CEO

Dennis McGrath - EVP, CFO

Conference Call Participants

Ed Woo - Ascendiant Capital

Kyle Mikson - Canaccord

Mark Massaro - BTIG

Mike Matson - Needham & Co.

Operator

Good day, and welcome to the Lucid Diagnostics Second Quarter 2023 Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Michael Parks, VP, Investor Relations. Please go ahead.

Michael Parks

Thank you, Betsy. Good morning, everyone. Thank you for participating in today's second quarter 2023 business update call.

The press release announcing our business update for the company and financial results for the 3 and 6 months ended June 30, 2023, is available on the Lucid website.

Please take a moment to read the disclaimer about forward-looking statements in the press release. The business update, press release and this conference call include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer in our filings with the U.S. Securities and Exchange Commission.

For a list and description of these and other important risks and uncertainties that may affect future operations, see Part I, Item 1A, entitled Risk Factors, and Lucid's most recent annual report on Form 10-Q filed with the SEC and subsequent updates filed and quarterly reports on Form 10-Q and any subsequent Form 8-K filings. Except as required by law, Lucid disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes in expectations or in events, conditions or circumstances on which the expectations may be based or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

I would now like to turn the call over to Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics. Dr. Aklog?

Lishan Aklog

Thank you, Mike, and thank you, everyone, for joining us this morning. I appreciate you taking the time. We look forward to providing you an update of the last quarter. As we mentioned in the press release yesterday, we really closed out very strongly for the first half of this year. So let's just start with some of the second quarter highlights.